Expression Pathology to ID Cancer Protein Biomarkers for Roche's Drug Development Pipeline
January 14, 2011
Expression Pathology to ID Cancer Protein Biomarkers for Roche's Drug Development Pipeline
Under the terms of the deal, Expression Pathology will use its Liquid Tissue SRM technology to develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in FFPE tissue samples.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 7, 2011 / ProteoMonitor - Phosphoproteomic Screens Elucidate Feedback Loop Linked to mTOR Inhibitor Resistance
June 17, 2011 / ProteoMonitor - RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor